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The genetic testing in various clinical conditions emerges
to have an important role in both diagnosis and treatment.
Recently, a revolution in genomic technologies from the first-
generation Sanger method to next-generation high through-
put sequencing and microarrays has occurred. All of these
technologies have been widely applied for genome, exome,
transcriptome sequencing, and epigenomics.The conclusions
from basic research resulted in the development of new pro-
tocols with great potential for clinical application. Selected
examples of their clinical use include breakthroughs in prena-
tal screening, identification of rare genetic variants associated
with monogenic Mendelian disorders, and efficient detection
of either inherited or somatic mutations in cancer genes.This
special issue is addressing laboratory genetic testing in prac-
tice, moving beyond classical concept of patient approach.
Personalized medicine, which may provide accurate and
effective treatment option in most of the human diseases in
the future, will offer the promise of altering conventional
medicine. Diagnosis, clinical findings, and treatment options
vary in every individual. Thus, it is important to clarify wide
spectrum of clinical and laboratory findings in examined
patients. In this special issue, researchers present various
cases and studies emphasizing the importance of clinical,
laboratory, and genetic findings which will be beneficial in
clinical practice. Among them there is ischemic stroke (IS)
which is one of the important causes of morbidity and mor-
tality. The authors showed that Vitamin K epoxide reductase
complex subunit 1- (VKORC1-) 1639A allele can be a possible
genetic risk factor for IS in Ukrainian population. On the
other hand precisionmedicine mentioned above is one of the
current models, which tries to explain the genetic indicators
to improve the quality of medical care in recent days.
Another paper points to molecular diagnostics for precision
medicine in colorectal cancer (CRC). The authors discuss
the future perspectives of CRC heterogeneity associated
with anti-EGFR resistance and immune checkpoint blockage
therapy. Authors of another paper find NGS data analysis
problematic when the differentiation of the indel errors and
false positive mutations is needed. The authors propose new
software AGSA helping to detect false positive mutations in
homopolymeric sequences at lower costs and in shorted time
while increasing reliability, notably for homopolymer tracts.
Tissue sampling and microdissection are very important
steps in the molecular genetic analysis of cancer samples.
This was described on the basis of microdissection strategy in
pulmonary tumor. The authors demonstrate the importance
of microdissection in morphologically different tumor com-
ponents for pyrosequencing in KRAS and BRAF mutations.
Despite rapid technological advances in medicine, essential
hypertension (EH) etiology remains largely unknown. We
publish the first research assessing the atrial natriuretic
peptide gene polymorphisms in both EH and type 2 diabetes
mellitus patients amongMalaysian population. Copy number
variations (CNVs) have attracted increasing attention as can-
cer susceptibility regulators. Further paper describes CNV-
67048 of WW domain-containing oxidoreductase which is
shown to be a risk factor of epithelial ovarian cancer in
Chinese population. CNV based microarray is an important
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technology which provides to investigate the CNV of whole
genome. The detection rate and pathogenic yield of chro-
mosomalmicroarray analysis (CMA) in neurodevelopmental
disorders are described.The authors established the detection
rate and pathogenic yield of CMA as depending on the
primary indications for testing, the age of the individuals
tested, and the specialty of the ordering doctor. Targeted
sequencing is the method of choice for examining genes in
specific pathways or in genetic heterogeneity which is respon-
sible for many systemic disorders. Further article describes
targeted sequencing in inherited retinal dystrophies (IRD).
The study demonstrates that NGS represents a comprehen-
sive cost-effective approach for IRDs molecular diagnosis.
The identification of the genetic alterations underlying the
phenotype enabled the clinicians to achieve a more accurate
diagnosis.The results emphasize the importance ofmolecular
diagnosis coupled with clinic information to unravel the
extensive phenotypic heterogeneity of these diseases.
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